Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Clin Cancer Res. 2019 Jul 2;25(18):5608–5622. doi: 10.1158/1078-0432.CCR-18-2387

Figure 4. DNAPK inhibition reduces Wnt signaling in CRPC cells.

Figure 4.

(A and B), Bar graphs show the expression of Wnt pathway genes after knockdown (via siRNA) or inhibition (via NU7441, 1 μM) of DNAPK in LNCaP-AR cells (N=2, in duplicates). (C and D), Immunoblot analyses show the effect of DNAPK knockdown (via siRNA) or inhibition (via NU7441 1 μM) on indicated proteins in LNCaP-AR and C4-2B cells. E, Representative images (magnification 20X) demonstrate the effect of DNAPK inhibition (via NU7441 or the clinical-grade DNAPK inhibitor CC-115, 1 μM) on invasion and migration of LNCaP-AR and C4-2B cells (N=3 in duplicates). Recombinant human WNT3A (200 ng/ml) was used to stimulate Wnt signaling (C-E). Bar graphs represent the quantification of invaded/migrated cells. F, Images (magnification 20X) display the effect of DNAPK inhibition (via NU7441 or CC-115) on invasion and migration of enzalutamide resistant LNCaP-AR (LNCaP-AR-enza-res) cells. Bar graphs show quantification of invaded/migrated cells. All data are represented as mean ± SEM *= p < 0.05 compared to respective controls and were calculated using two-way ANOVA (Figure 4A, 4B, 4E) or one way AVOVA (Figure 4F). Graphs and statistical analyses were done on GraphPad Prism software. RQ = relative quantity.